


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Applicants : Tadao OHNO et al.

Group Art Unit : 1645

Appl. No. : 10/505,452 ✓
(U.S. National Stage of PCT/JP02/02013)

Examiner : Not Yet Assigned

I.A. Filed : March 5, 2002

Confirmation No. : 7197

For : SOLIDIFIED TISSUE IMMUNOADJUVANT

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Window, Mail Stop Amendment
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir :

In accordance with the duty of disclosure under 37 C.F.R. §1.56 and §§1.97-1.98, Applicants hereby bring the following information to the attention of the Examiner in charge of the above-identified application, which includes information cited and discussed in the specification, the International Search Report, and the International Preliminary Examination Report issued in connection with International Patent Application No. PCT/JP02/02013, of which the present application is the U.S. National Stage Application. Copies of the International Search Report (in English and Japanese) and the International Preliminary Examination Report (in Japanese) were enclosed with the papers when entering the National Stage on September 1, 2004. A copy of the International Preliminary Examination Report in English is attached hereto. The

Examiner is invited to review these materials to inspect the relevance indicated during international examination with respect to the documents cited therein.

The following is a list of the documents cited in the above-noted documents:

Dendritic Cells, Second Edition, Ed. By MT LOTZE et al., Academic Press, San Diego, 2001. Applicants note that this document is cited on page 1 of the specification of the present application;

U.S. Patent No. 4,663,306. Applicants note that this document is cited on page 2 of the specification of the present application;

J.D. GEIGER et al., Cancer Res., Vol. 61, pp. 8513-8519, 2001. Applicants note that this document is cited on page 2 of the specification of the present application;

K.A. WILKINSON et al., J. Immunol. Methods, Vol. 235, pp. 1-9, 2000. Applicants note that this document is cited on page 2 of the specification of the present application;

H.M. VORDERMEIER et al., Vaccine, Vol. 13, pp. 1576-1582, 1995. Applicants note that this document is cited on page 3 of the specification of the present application;

H.C. ERTL et al., Vaccine, Vol. 14, pp. 879-885, 1996. Applicants note that this document is cited on page 3 of the specification of the present application;

D.H. JONES et al., J. Biotechnology, Vol. 44, pp. 29-36, 1996. Applicants note that this document is cited on page 3 of the specification of the present application;

N. VENKATAPRASAD et al., Vaccine, Vol. 17, pp. 1814-1819, 1999.

Applicants note that this document is cited on page 3 of the specification of the present application;

International Patent Application No. PCT/JP00/00692, which published as International Patent Application Publication No. WO 00/47226, together with patent family member European Patent Application Publication No. EP 1 159 967. Applicants note that this document is cited on page 3 of the specification of the present application; and

K.M. DHODAPKAR et al., J. Exp. Med., Vol. 195, pp. 125-133, 2002.

Applicants note that this document is cited on page 4 of the specification of the present application.

Further to 37 C.F.R. §1.98 (a)(2)(ii), a copy of the U.S. patent is not enclosed herewith. However, if a copy is needed, the Examiner is respectfully requested to contact the undersigned.

Applicants also submit herewith a copy of a Taiwanese Office Action that was mailed on April 20, 2004, in which the following documents were cited:

International Patent Application Publication No. WO 00/47226 (mentioned above); and

B.G. PENG et al., Jpn. J. Cancer Res., Vol. 93, No. 4, pp. 363-368, 2002, together with an English language Abstract of the same.

Applicants also bring the following co-pending, commonly assigned patent applications to the Examiner's attention:

U.S. Patent Application No. 10/510,708 to OHNO et al., which was filed on October 15, 2004; and

U.S. Patent Application No. 09/890,266 to OHNO et al., which was filed on March 27, 2002.


Further to the U.S. Patent and Trademark Office's decision to waive the requirement under 37 C.F.R. §1.98 (a)(2)(iii) if the U.S. patent application was filed after June 30, 2003, only a copy of U.S. Patent Application No. 09/890,266 is enclosed herewith. However, if a copy of the other U.S. Patent Application is needed, the Examiner is respectfully requested to contact the undersigned.

Copies of the above-noted documents except the U.S. patent and U.S. Patent Application No. 10/510,708 are enclosed together with a duly completed Form PTO-1449. The Examiner is accordingly requested to consider each of these documents, and to make them of record in this application by initialing in the appropriate spaces on the Form PTO-1449. Applicants respectfully request that the Examiner include a copy of the initialed Form PTO-1449 with the next communication from the U.S. Patent and Trademark Office.

Applicants note that an Office Action on the merits has not issued in the present application, and thus no fee is believed necessary to ensure consideration of the submitted material. However, if an Office Action on the merits has issued and is crossing this statement in the mail, the undersigned hereby authorizes the Commissioner to charge any fee necessary for the consideration of this statement, including any payment under 37 C.F.R. §1.17 (p) to Deposit Account No. 19-0089.

Should there be any questions, the Examiner is invited to contact the undersigned at the below-listed telephone number.

Respectfully Submitted,
Tadao OHNO et al.

A handwritten signature in black ink, appearing to read "Stephen M. Roylance", written over a horizontal line.

Bruce H. Bernstein
Reg. No. 29,027

Stephen M. Roylance
Reg. No. 31,296

April 19, 2005
GREENBLUM & BERNSTEIN, P.L.C.
1950 Roland Clarke Place
Reston, VA 20191
(703) 716-1191

